Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02947685 · OUTCOME

Progression-free Survival (PFS) as Assessed by Investigator

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · Source last updated 2026-02-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
7 years 3 months

What was measured

The time from registration to disease progression or death.

Groups in this outcome

Arm A

Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)

Arm B

AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A261
Arm B257

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm A44.3Not reported32.456.8Not reported
Arm B29.1Not reported23.338.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        32.4
        upper Limit
        56.8
        value
        44.3
      2. group Id
        OG001
        lower Limit
        23.3
        upper Limit
        38.6
        value
        29.1
denoms
  1. counts
    1. group Id
      OG000
      value
      261
    2. group Id
      OG001
      value
      257
    units
    Participants
description
The time from registration to disease progression or death.
dispersion Type
95% Confidence Interval
groups
  1. description
    Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)
    id
    OG000
    title
    Arm A
  2. description
    AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)
    id
    OG001
    title
    Arm B
param Type
MEDIAN
reporting Status
POSTED
time Frame
7 years 3 months
title
Progression-free Survival (PFS) as Assessed by Investigator
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice